Lyra Historical Balance Sheet

LYRA Stock

USD 0.15 0.01 3.13%

Trend analysis of Lyra Therapeutics balance sheet accounts such as Total Stockholder Equity of 11 M provides information on Lyra Therapeutics' total assets, liabilities, and equity, which is the actual value of Lyra Therapeutics to its prevalent stockholders. By breaking down trends over time using Lyra Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Lyra Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lyra Therapeutics is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

About Lyra Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lyra Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Lyra Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lyra Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lyra currently owns. An asset can also be divided into two categories, current and non-current.

Lyra Therapeutics Balance Sheet Chart

At present, Lyra Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 17 M, whereas Other Current Liabilities is forecasted to decline to about 5 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Lyra Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lyra Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lyra Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lyra Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Lyra Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lyra Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.At present, Lyra Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 17 M, whereas Other Current Liabilities is forecasted to decline to about 5 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	9.0M	9.4M	6.9M	5.0M
Total Assets	110.0M	142.6M	66.3M	77.8M

Other Current Liab Total Assets

Lyra Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.92	0.83	0.85	0.79	0.88	0.8	0.09	-0.72	0.8	0.41	0.83	0.8	0.83	0.98	-0.25	0.68	-0.66	0.84	0.66	0.88	-0.62	0.85	0.77	0.98	0.95
Other Current Liab	0.92		0.84	0.73	0.9	0.83	0.8	0.31	-0.82	0.77	0.21	0.84	0.93	0.86	0.86	-0.33	0.78	-0.54	0.79	0.61	0.84	-0.49	0.73	0.77	0.87	0.81
Total Current Liabilities	0.83	0.84		0.84	0.77	0.84	0.78	0.2	-0.78	0.96	0.3	0.81	0.79	0.76	0.76	-0.32	0.71	-0.77	0.86	0.82	0.88	-0.72	0.84	0.76	0.77	0.65
Total Stockholder Equity	0.85	0.73	0.84		0.7	0.87	0.67	-0.07	-0.67	0.8	0.52	0.71	0.73	0.8	0.84	-0.24	0.6	-0.95	0.88	0.75	0.94	-0.93	1.0	0.64	0.84	0.77
Other Liab	0.79	0.9	0.77	0.7		0.85	0.77	0.44	-0.96	0.65	0.22	0.82	0.88	0.97	0.72	-0.69	0.96	-0.61	0.83	0.54	0.84	-0.57	0.7	0.86	0.72	0.65
Net Tangible Assets	0.88	0.83	0.84	0.87	0.85		0.71	-0.05	-0.86	0.74	0.66	0.74	0.71	0.91	0.85	-0.53	0.79	-0.78	0.99	0.85	0.97	-0.75	0.87	0.76	0.86	0.8
Property Plant And Equipment Net	0.8	0.8	0.78	0.67	0.77	0.71		0.49	-0.8	0.65	0.14	1.0	0.68	0.76	0.66	-0.36	0.8	-0.52	0.69	0.42	0.78	-0.47	0.67	0.96	0.66	0.58
Net Debt	0.09	0.31	0.2	-0.07	0.44	-0.05	0.49		-0.41	0.13	-0.71	0.49	0.43	0.29	-0.07	-0.36	0.52	0.1	-0.05	-0.33	0.02	0.13	-0.07	0.53	-0.07	-0.13
Retained Earnings	-0.72	-0.82	-0.78	-0.67	-0.96	-0.86	-0.8	-0.41		-0.62	-0.31	-0.82	-0.76	-0.95	-0.62	0.76	-0.99	0.61	-0.86	-0.6	-0.85	0.58	-0.67	-0.9	-0.63	-0.54
Accounts Payable	0.8	0.77	0.96	0.8	0.65	0.74	0.65	0.13	-0.62		0.23	0.69	0.74	0.64	0.77	-0.19	0.55	-0.73	0.77	0.8	0.77	-0.68	0.8	0.63	0.77	0.67
Cash	0.41	0.21	0.3	0.52	0.22	0.66	0.14	-0.71	-0.31	0.23		0.14	0.01	0.39	0.48	-0.24	0.21	-0.51	0.67	0.71	0.58	-0.52	0.52	0.18	0.48	0.49
Non Current Assets Total	0.83	0.84	0.81	0.71	0.82	0.74	1.0	0.49	-0.82	0.69	0.14		0.75	0.81	0.7	-0.36	0.82	-0.56	0.72	0.46	0.81	-0.51	0.71	0.95	0.7	0.62
Non Currrent Assets Other	0.8	0.93	0.79	0.73	0.88	0.71	0.68	0.43	-0.76	0.74	0.01	0.75		0.84	0.75	-0.32	0.74	-0.61	0.68	0.49	0.76	-0.57	0.73	0.67	0.75	0.68
Other Assets	0.83	0.86	0.76	0.8	0.97	0.91	0.76	0.29	-0.95	0.64	0.39	0.81	0.84		0.77	-0.66	0.93	-0.72	0.89	0.6	0.91	-0.7	0.8	0.85	0.77	0.72
Cash And Short Term Investments	0.98	0.86	0.76	0.84	0.72	0.85	0.66	-0.07	-0.62	0.77	0.48	0.7	0.75	0.77		-0.19	0.57	-0.64	0.81	0.68	0.83	-0.6	0.84	0.63	1.0	0.99
Net Receivables	-0.25	-0.33	-0.32	-0.24	-0.69	-0.53	-0.36	-0.36	0.76	-0.19	-0.24	-0.36	-0.32	-0.66	-0.19		-0.81	0.31	-0.55	-0.29	-0.41	0.31	-0.24	-0.61	-0.19	-0.14
Common Stock Shares Outstanding	0.68	0.78	0.71	0.6	0.96	0.79	0.8	0.52	-0.99	0.55	0.21	0.82	0.74	0.93	0.57	-0.81		-0.55	0.79	0.48	0.77	-0.52	0.6	0.91	0.57	0.49
Non Current Liabilities Total	-0.66	-0.54	-0.77	-0.95	-0.61	-0.78	-0.52	0.1	0.61	-0.73	-0.51	-0.56	-0.61	-0.72	-0.64	0.31	-0.55		-0.82	-0.73	-0.86	1.0	-0.95	-0.53	-0.64	-0.55
Capital Surpluse	0.84	0.79	0.86	0.88	0.83	0.99	0.69	-0.05	-0.86	0.77	0.67	0.72	0.68	0.89	0.81	-0.55	0.79	-0.82		0.88	0.96	-0.79	0.88	0.75	0.81	0.74
Other Current Assets	0.66	0.61	0.82	0.75	0.54	0.85	0.42	-0.33	-0.6	0.8	0.71	0.46	0.49	0.6	0.68	-0.29	0.48	-0.73	0.88		0.8	-0.69	0.75	0.44	0.69	0.6
Other Stockholder Equity	0.88	0.84	0.88	0.94	0.84	0.97	0.78	0.02	-0.85	0.77	0.58	0.81	0.76	0.91	0.83	-0.41	0.77	-0.86	0.96	0.8		-0.83	0.94	0.77	0.83	0.76
Total Liab	-0.62	-0.49	-0.72	-0.93	-0.57	-0.75	-0.47	0.13	0.58	-0.68	-0.52	-0.51	-0.57	-0.7	-0.6	0.31	-0.52	1.0	-0.79	-0.69	-0.83		-0.93	-0.49	-0.6	-0.53
Net Invested Capital	0.85	0.73	0.84	1.0	0.7	0.87	0.67	-0.07	-0.67	0.8	0.52	0.71	0.73	0.8	0.84	-0.24	0.6	-0.95	0.88	0.75	0.94	-0.93		0.64	0.84	0.77
Property Plant And Equipment Gross	0.77	0.77	0.76	0.64	0.86	0.76	0.96	0.53	-0.9	0.63	0.18	0.95	0.67	0.85	0.63	-0.61	0.91	-0.53	0.75	0.44	0.77	-0.49	0.64		0.64	0.55
Total Current Assets	0.98	0.87	0.77	0.84	0.72	0.86	0.66	-0.07	-0.63	0.77	0.48	0.7	0.75	0.77	1.0	-0.19	0.57	-0.64	0.81	0.69	0.83	-0.6	0.84	0.64		0.99
Net Working Capital	0.95	0.81	0.65	0.77	0.65	0.8	0.58	-0.13	-0.54	0.67	0.49	0.62	0.68	0.72	0.99	-0.14	0.49	-0.55	0.74	0.6	0.76	-0.53	0.77	0.55	0.99

Click cells to compare fundamentals

Lyra Therapeutics Account Relationship Matchups

Lyra Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	80.8M	54.9M	110.0M	142.6M	66.3M	77.8M
Other Current Liab	2.0M	3.2M	9.0M	9.4M	6.9M	5.0M
Total Current Liabilities	4.9M	18.2M	14.5M	19.6M	12.6M	12.1M
Total Stockholder Equity	74.5M	34.3M	80.8M	89.4M	11.6M	11.0M
Net Tangible Assets	(123.3M)	74.5M	34.3M	80.8M	92.9M	97.5M
Property Plant And Equipment Net	3.4M	4.5M	5.9M	35.3M	21.3M	11.8M
Net Debt	(72.2M)	(44.3M)	(30.3M)	4.5M	(6.2M)	(6.5M)
Retained Earnings	(149.9M)	(193.4M)	(248.7M)	(311.4M)	(404.8M)	(384.6M)
Accounts Payable	922K	3.1M	2.6M	3.1M	1.2M	2.0M
Cash	74.6M	45.7M	32.6M	22.4M	40.6M	39.2M
Non Current Assets Total	4.9M	6.9M	9.1M	37.8M	23.3M	13.7M
Non Currrent Assets Other	118K	762K	3.3M	2.5M	2.0M	1.6M
Other Assets	1.4M	2.7M	1.1M	4.7M	5.4M	5.6M
Cash And Short Term Investments	74.6M	45.7M	97.9M	102.8M	40.6M	62.1M
Common Stock Shares Outstanding	8.6M	13.0M	30.2M	49.8M	65.1M	68.4M
Liabilities And Stockholders Equity	80.8M	54.9M	110.0M	142.6M	66.3M	77.8M
Non Current Liabilities Total	1.5M	2.3M	14.7M	33.6M	42.1M	26.0M
Capital Lease Obligations	2.4M	1.5M	2.2M	26.9M	34.4M	36.1M
Other Current Assets	2.6M	4.3M	2.9M	2.1M	2.4M	2.5M
Other Stockholder Equity	305.2M	227.7M	329.4M	400.7M	416.3M	245.2M
Total Liab	6.3M	20.6M	29.2M	53.2M	54.8M	34.8M
Net Invested Capital	74.5M	34.3M	80.8M	89.4M	11.6M	11.0M
Property Plant And Equipment Gross	3.4M	4.5M	5.9M	37.2M	25.5M	26.7M
Total Current Assets	75.9M	47.9M	100.8M	104.8M	43.0M	64.0M
Accumulated Other Comprehensive Income	0.0	(80.8M)	10K	33K	38.0K	39.8K
Net Working Capital	71.0M	29.7M	86.4M	85.2M	30.4M	51.9M
Property Plant Equipment	3.4M	2.2M	5.9M	4.5M	5.1M	3.5M
Short Long Term Debt Total	2.4M	1.5M	2.2M	26.9M	34.4M	36.1M
Current Deferred Revenue	2.8M	9.8M	1.3M	1.7M	398K	378.1K
Short Term Debt	2.0M	2.1M	3.5M	8.9M	4.1M	4.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:

How To Invest In Lyra

Details

Is Lyra Stock a good investment?

Details

What is Lyra Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.43)

Revenue Per Share

0.024

Quarterly Revenue Growth

0.432

Return On Assets

(0.36)

Return On Equity

(1.85)

The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lyra Historical Balance Sheet

About Lyra Balance Sheet Analysis

Lyra Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Lyra Therapeutics balance sheet Correlations

Lyra Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lyra Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Capital Surpluse	+ 0.99	Net Tangible Assets
Net Working Capital	+ 0.99	Cash And Short Term Investments

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Retained Earnings	- 0.96	Other Liab
Net Invested Capital	- 0.95	Non Current Liabilities Total
Other Assets	- 0.95	Retained Earnings
Non Current Liabilities Total	- 0.95	Total Stockholder Equity
Net Invested Capital	- 0.93	Total Liab